神経遺伝学的検査の世界市場レポート 2025年

神経遺伝学的検査市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.5％で11億6,000万米ドルに成長します。予測期間の成長は、個別化医療におけるアプリケーションの拡大、慢性疾患の増加、病院数の増加、診断ラボ数の増加、疾患の早期発見に対する需要の高まりに起因しています。予測期間の主な動向には、技術の進歩、非侵襲的検査法の採用拡大、新製品開発、戦略的提携、神経疾患の新規バイオマーカーの出現などがあります。

神経疾患の増加が神経遺伝学的検査市場の成長を牽引すると予想されます。神経疾患には、脳、脊髄、神経を含む神経系に影響を及ぼす疾患が含まれます。これらの疾患は、遺伝的素因、感染症、外傷、毒素、自己免疫反応、変性などによって生じる。神経遺伝学的検査は、神経疾患の診断、治療、管理を強化する上で重要な役割を果たします。遺伝的危険因子に関する個別化された洞察を提供し、治療方針の決定を導き、患者や家族が十分な情報を得た上でヘルスケアを選択できるようにすることで、患者のケアと転帰を改善することができます。例えば、2022年4月にEuropean Brain Councilが報告したように、世界では600を超える神経疾患と300近くの精神疾患で数百万人が苦しんでおり、その中には6,500万人のてんかん患者も含まれています。欧州では1,050万人が認知症であり、2050年には1,870万人に増加すると予測されています。したがって、神経疾患の有病率の増加は、神経遺伝学的検査市場の成長を促進すると予想されます。

がんの有病率の上昇も神経遺伝学的検査市場を押し上げると予想されます。制御不能な細胞分裂と組織破壊を特徴とするがんは、肥満の流行、遺伝性遺伝子異常、B型肝炎やC型肝炎、エプスタイン・バーウイルス（EBV）、ヒトパピローマウイルス（HPV）などのウイルス感染などの要因により増加傾向にあります。神経遺伝学的検査は、最も効果的な治療法の選択、予後の評価、高リスク患者の特定、個人の遺伝子プロファイルや家族歴に基づいた個別化治療の提供に役立つため、がん管理にとって極めて重要です。例えば、米国臨床腫瘍学会（American Society of Clinical Oncology）は2024年5月に、2022年には推定2,000万人の新規がん症例が確認され、2050年には世界全体で3,500万人の新規症例が確認され、この疾患による死亡者は970万人に達するとの予測を報告しています。その結果、がんの有病率の増加が神経遺伝学的検査市場の成長を促進しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界神経遺伝学的検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の神経遺伝学的検査市場：成長率分析
• 世界の神経遺伝学的検査市場の実績：規模と成長, 2019-2024
• 世界の神経遺伝学的検査市場の予測：規模と成長, 2024-2029, 2034F
• 世界神経遺伝学的検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の神経遺伝学的検査市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• マイクロアレイ解析
• 全エクソームシーケンス（WES）
• マルチプレックスライゲーション依存プローブ増幅（MLPA）
• ポリメラーゼ連鎖反応（PCR）検査
• その他のタイプ
• 世界の神経遺伝学的検査市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 希少遺伝性疾患
• がん
• 嚢胞性線維症
• 鎌状赤血球貧血
• デュシェンヌ型筋ジストロフィー
• サラセミア
• ハンチントン病
• 脆弱X症候群
• その他の病気
• 世界の神経遺伝学的検査市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 調査機関
• 診断研究所
• 世界の神経遺伝学的検査市場マイクロアレイ解析の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 比較ゲノムハイブリダイゼーション（CGH）マイクロアレイ
• 一塩基多型（SNP）マイクロアレイ
• 遺伝子発現マイクロアレイ
• 世界の神経遺伝学的検査市場全エクソームシーケンス（WES）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• ターゲットエクソームシーケンシング
• 臨床エクソームシーケンシング
• 研究グレードのエクソームシーケンシング
• 世界の神経遺伝学的検査市場、マルチプレックスライゲーション依存プローブ増幅（MLPA）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• コピー数変異のためのMLPA
• メチル化分析のためのMLPA
• 特定疾患検出のためのMLPA
• 世界の神経遺伝学的検査市場ポリメラーゼ連鎖反応（PCR）検査の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 定量PCR（qPCR）
• 逆転写PCR（RT-PCR）
• デジタルPCR（dPCR）
• 世界の神経遺伝学的検査市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 次世代シーケンシング（NGS）
• サザンブロッティング
• 蛍光in situハイブリダイゼーション（FISH）
• サンガーシーケンス

第7章 地域別・国別分析

• 世界の神経遺伝学的検査市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の神経遺伝学的検査市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 神経遺伝学的検査市場：競合情勢
• 神経遺伝学的検査市場：企業プロファイル
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • Roche Diagnostics Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Laboratory Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eurofins Scientific Inc.
• Agilent Technologies Inc.
• PerkinElmer Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• QIAGEN N.V.
• Exact Sciences Corporation
• Myriad Genetics Inc.
• BioReference Laboratories Inc.
• Connecticut Children's
• Invitae Corp.
• Ambry Genetics Corporation
• Fulgent Genetics Inc.
• Blueprint Genetics Inc.
• GeneDx LLC

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 神経遺伝学的検査市場2029：新たな機会を提供する国
• 神経遺伝学的検査市場2029：新たな機会を提供するセグメント
• 神経遺伝学的検査市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Neurogenetic testing is a form of genetic testing that focuses on identifying genetic variations linked to neurological disorders or conditions impacting the nervous system. It aids in diagnosis, prediction, and management of neurological disorders, supports research, and helps develop personalized treatment strategies in neurology and genetics.

The main types of neurogenetic testing in the market include microarray analysis, whole-exome sequencing (WES), multiplex ligation-dependent probe amplification (MLPA), polymerase chain reaction (PCR) tests, and others. Microarray analysis is a technique in neurogenetic testing that simultaneously assesses the expression levels of thousands of genes. These tests are used for various diseases such as rare genetic disorders, cancer, cystic fibrosis, sickle cell anemia, Duchenne muscular dystrophy, thalassemia, Huntington's disease, fragile X syndrome, and others. They are utilized by hospitals, specialty clinics, research institutes, and diagnostics laboratories.

The neurogenetic testing market research report is one of a series of new reports from The Business Research Company that provides neurogenetic testing market statistics, including neurogenetic testing industry global market size, regional shares, competitors with a neurogenetic testing market share, detailed neurogenetic testing market segments, market trends, and opportunities, and any further data you may need to thrive in the neurogenetic testing industry. This neurogenetic testing research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurogenetic testing market size has grown rapidly in recent years. It will grow from $0.61 billion in 2024 to $0.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.9%. The growth in the historic period can be attributed to increased prevalence of neurological disease cases, increase research in life science domain, increasing prevalence of parkinson's disease, increased cases of cancer, and rising awareness among healthcare professionals.

The neurogenetic testing market size is expected to see rapid growth in the next few years. It will grow to $1.16 billion in 2029 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to expanding applications in personalized medicine, rise in chronic diseases, increased number of hospitals, increased number of diagnostic laboratories and growing demand for early disease detection. Major trends in the forecast period include technological advancement, greater adoption of non-invasive testing methods, new product development, strategic collaborations, and the emergence of novel biomarkers for neurological conditions.

The increase in neurological disorders is expected to drive the growth of the neurogenetic testing market. Neurological disorders encompass conditions affecting the nervous system, including the brain, spinal cord, and nerves. These disorders can arise from genetic predisposition, infections, trauma, toxins, autoimmune responses, or degeneration. Neurogenetic testing plays a crucial role in enhancing the diagnosis, treatment, and management of neurological disorders. It provides personalized insights into genetic risk factors, guides treatment decisions, and empowers patients and families to make informed healthcare choices, thereby improving patient care and outcomes. For example, as reported by the European Brain Council in April 2022, millions globally suffer from over 600 neurological diseases and nearly 300 psychiatric conditions, including 65 million with epilepsy. In Europe, 10.5 million people have dementia, with projections indicating a rise to 18.7 million by 2050. Hence, the increasing prevalence of neurological disorders is expected to fuel the growth of the neurogenetic testing market.

The rising prevalence of cancer is also expected to boost the neurogenetic testing market. Cancer, characterized by uncontrolled cell division and tissue destruction, is on the rise due to factors such as the obesity epidemic, inherited genetic abnormalities, and viral infections such as hepatitis B and C, Epstein-Barr virus (EBV), and human papillomavirus (HPV). Neurogenetic testing is crucial for cancer management as it aids in selecting the most effective treatment, assessing prognoses, identifying high-risk patients, and providing personalized care based on individual genetic profiles and family history. For instance, the American Society of Clinical Oncology reported in May 2024 that an estimated 20 million new cancer cases were identified in 2022, with projections of 35 million new cases globally by 2050, leading to 9.7 million deaths from the disease. Consequently, the increasing prevalence of cancer is propelling the growth of the neurogenetic testing market.

Major companies are focusing on developing innovative products such as whole-genome sequencing to improve genetic analysis accuracy and scope. Whole-genome sequencing (WGS) is a comprehensive genetic testing method that involves determining an individual's entire genome DNA sequence. For instance, Nucleus Genomics, a US-based company specializing in genetic analysis, launched a DNA analysis product in March 2024. This platform provides people with a deeper understanding of their genetic predispositions, enabling informed decisions about health and well-being. Nucleus Genomics aims to redefine genetic testing by offering cutting-edge technology and expert genetic counseling services, making whole-genome sequencing accessible and revolutionizing genomic medicine.

Major companies operating in the neurogenetic testing market are Thermo Fisher Scientific Inc., Mayo Clinic, Roche Diagnostics Corporation, Laboratory Corporation, Quest Diagnostics Incorporated, Eurofins Scientific Inc., Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Exact Sciences Corporation, Myriad Genetics Inc., BioReference Laboratories Inc., Connecticut Children's, Invitae Corp., Ambry Genetics Corporation, Fulgent Genetics Inc., Blueprint Genetics Inc., GeneDx LLC, Pacific Biosciences of California Inc., MedGenome Labs, CENTOGENE, Baylor Genetics, Victorian Clinical Genetics Services

North America was the largest region in the neurogenetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurogenetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neurogenetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenetic testing market includes revenues earned by entities by providing services such as diagnostic testing, predictive testing, carrier screening, and prenatal testing and related products such as genetic testing kits, DNA sequencing platforms, and bioinformatics software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenetic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenetic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurogenetic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurogenetic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Microarray Analysis; Whole-Exome Sequencing (WES); Multiplex Ligation Dependent Probe Amplification (MLPA); Polymerase Chain Reaction (PCR) Tests; Other Types
• 2) By Disease: Rare Genetic Disorder; Cancer; Cystic Fibrosis; Sickle Cell Anemia; Duchenne Muscular Dystrophy; Thalassemia; Huntington's Disease; Fragile X Syndrome; Other Diseases
• 3) By End-Users: Hospitals; Specialty Clinics; Research Institutes; Diagnostics Laboratories
• Subsegments:
• 1) By Microarray Analysis: Comparative Genomic Hybridization (CGH) Microarray; Single Nucleotide Polymorphism (SNP) Microarray; Gene Expression Microarray
• 2) By Whole-Exome Sequencing (WES): Targeted Exome Sequencing; Clinical Exome Sequencing; Research-Grade Exome Sequencing
• 3) By Multiplex Ligation Dependent Probe Amplification (MLPA): MLPA For Copy Number Variation; MLPA For Methylation Analysis; MLPA For Specific Disease Detection
• 4) By Polymerase Chain Reaction (PCR) Tests: Quantitative PCR (qPCR); Reverse Transcription PCR (RT-PCR); Digital PCR (dPCR)
• 5) By Other Types: Next-Generation Sequencing (NGS); Southern Blotting; Fluorescence In Situ Hybridization (FISH); Sanger Sequencing
• Companies Mentioned: Thermo Fisher Scientific Inc.; Mayo Clinic; Roche Diagnostics Corporation; Laboratory Corporation; Quest Diagnostics Incorporated
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurogenetic Testing Market Characteristics

3. Neurogenetic Testing Market Trends And Strategies

4. Neurogenetic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Neurogenetic Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Neurogenetic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Neurogenetic Testing Market Growth Rate Analysis
• 5.4. Global Neurogenetic Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Neurogenetic Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Neurogenetic Testing Total Addressable Market (TAM)

6. Neurogenetic Testing Market Segmentation

• 6.1. Global Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Microarray Analysis
• Whole-Exome Sequencing (WES)
• Multiplex Ligation Dependent Probe Amplification (MLPA)
• Polymerase Chain Reaction (PCR) Tests
• Other Types
• 6.2. Global Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Rare Genetic Disorder
• Cancer
• Cystic Fibrosis
• Sickle Cell Anemia
• Duchenne Muscular Dystrophy
• Thalassemia
• Huntington's Disease
• Fragile X Syndrome
• Other Diseases
• 6.3. Global Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Research Institutes
• Diagnostics Laboratories
• 6.4. Global Neurogenetic Testing Market, Sub-Segmentation Of Microarray Analysis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Comparative Genomic Hybridization (CGH) Microarray
• Single Nucleotide Polymorphism (SNP) Microarray
• Gene Expression Microarray
• 6.5. Global Neurogenetic Testing Market, Sub-Segmentation Of Whole-Exome Sequencing (WES), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Exome Sequencing
• Clinical Exome Sequencing
• Research-Grade Exome Sequencing
• 6.6. Global Neurogenetic Testing Market, Sub-Segmentation Of Multiplex Ligation Dependent Probe Amplification (MLPA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• MLPA For Copy Number Variation
• MLPA For Methylation Analysis
• MLPA For Specific Disease Detection
• 6.7. Global Neurogenetic Testing Market, Sub-Segmentation Of Polymerase Chain Reaction (PCR) Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Quantitative PCR (qPCR)
• Reverse Transcription PCR (RT-PCR)
• Digital PCR (dPCR)
• 6.8. Global Neurogenetic Testing Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Next-Generation Sequencing (NGS)
• Southern Blotting
• Fluorescence In Situ Hybridization (FISH)
• Sanger Sequencing

7. Neurogenetic Testing Market Regional And Country Analysis

• 7.1. Global Neurogenetic Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Neurogenetic Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurogenetic Testing Market

• 8.1. Asia-Pacific Neurogenetic Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurogenetic Testing Market

• 9.1. China Neurogenetic Testing Market Overview
• 9.2. China Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurogenetic Testing Market

• 10.1. India Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurogenetic Testing Market

• 11.1. Japan Neurogenetic Testing Market Overview
• 11.2. Japan Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurogenetic Testing Market

• 12.1. Australia Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurogenetic Testing Market

• 13.1. Indonesia Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurogenetic Testing Market

• 14.1. South Korea Neurogenetic Testing Market Overview
• 14.2. South Korea Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurogenetic Testing Market

• 15.1. Western Europe Neurogenetic Testing Market Overview
• 15.2. Western Europe Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurogenetic Testing Market

• 16.1. UK Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurogenetic Testing Market

• 17.1. Germany Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurogenetic Testing Market

• 18.1. France Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurogenetic Testing Market

• 19.1. Italy Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurogenetic Testing Market

• 20.1. Spain Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurogenetic Testing Market

• 21.1. Eastern Europe Neurogenetic Testing Market Overview
• 21.2. Eastern Europe Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurogenetic Testing Market

• 22.1. Russia Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurogenetic Testing Market

• 23.1. North America Neurogenetic Testing Market Overview
• 23.2. North America Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurogenetic Testing Market

• 24.1. USA Neurogenetic Testing Market Overview
• 24.2. USA Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurogenetic Testing Market

• 25.1. Canada Neurogenetic Testing Market Overview
• 25.2. Canada Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurogenetic Testing Market

• 26.1. South America Neurogenetic Testing Market Overview
• 26.2. South America Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurogenetic Testing Market

• 27.1. Brazil Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurogenetic Testing Market

• 28.1. Middle East Neurogenetic Testing Market Overview
• 28.2. Middle East Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurogenetic Testing Market

• 29.1. Africa Neurogenetic Testing Market Overview
• 29.2. Africa Neurogenetic Testing Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Neurogenetic Testing Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Neurogenetic Testing Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurogenetic Testing Market Competitive Landscape And Company Profiles

• 30.1. Neurogenetic Testing Market Competitive Landscape
• 30.2. Neurogenetic Testing Market Company Profiles
  • 30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Diagnostics Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Laboratory Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

31. Neurogenetic Testing Market Other Major And Innovative Companies

• 31.1. Eurofins Scientific Inc.
• 31.2. Agilent Technologies Inc.
• 31.3. PerkinElmer Inc.
• 31.4. Illumina Inc.
• 31.5. Bio-Rad Laboratories Inc.
• 31.6. QIAGEN N.V.
• 31.7. Exact Sciences Corporation
• 31.8. Myriad Genetics Inc.
• 31.9. BioReference Laboratories Inc.
• 31.10. Connecticut Children's
• 31.11. Invitae Corp.
• 31.12. Ambry Genetics Corporation
• 31.13. Fulgent Genetics Inc.
• 31.14. Blueprint Genetics Inc.
• 31.15. GeneDx LLC

32. Global Neurogenetic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurogenetic Testing Market

34. Recent Developments In The Neurogenetic Testing Market

35. Neurogenetic Testing Market High Potential Countries, Segments and Strategies

• 35.1 Neurogenetic Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Neurogenetic Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Neurogenetic Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer